ID

16387

Beschreibung

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00431795

Link

https://clinicaltrials.gov/show/NCT00431795

Stichworte

Versionen (1)
  1. 14.07.16 14.07.16 -
Hochgeladen am

14. Juli 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00431795

Englisch

Eligibility Breast Cancer NCT00431795

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
age 18-75 years
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
eastern cooperative oncology group (ecog) performance status 0-2
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
adequate bone marrow function (absolute neutrophil count >1000/mm^3, platelet count>100000/mm^3, hemoglobin>9gr/mm^3)
Beschreibung

Bone Marrow function | Absolute neutrophil count | Platelet Count measurement | Hemoglobin

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0019046
histologically- or cytologically- confirmed breast adenocarcinoma
Beschreibung

Breast adenocarcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0858252
no prior anthracycline-based chemotherapy as treatment of advanced breast cancer
Beschreibung

Anthracycline Antibiotics | Therapeutic procedure Advanced breast cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C0003234
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C3495917
no prior chemotherapy with ≥ 300mg/m2 doxorubicin or ≥ 540mg/m2 epirubicin as adjuvant setting
Beschreibung

Prior Chemotherapy | Doxorubicin Adjuvant | Epirubicin Adjuvant

Datentyp

boolean

Alias
UMLS CUI [1]
C1514457
UMLS CUI [2,1]
C0013089
UMLS CUI [2,2]
C1522673
UMLS CUI [3,1]
C0014582
UMLS CUI [3,2]
C1522673
at least 4 weeks interval since prior anticancer treatment
Beschreibung

Interval Minimum Since cancer treatment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1272706
UMLS CUI [1,2]
C1524031
UMLS CUI [1,3]
C1711239
UMLS CUI [1,4]
C0920425
measurable disease as defined by the presence of at least one measurable lesion(except bone metastases, ascites or pleural effusions)
Beschreibung

Measurable lesion Quantity | Secondary malignant neoplasm of bone | Ascites | Pleural effusion

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
UMLS CUI [2]
C0153690
UMLS CUI [3]
C0003962
UMLS CUI [4]
C0032227
life expectancy > 3 months
Beschreibung

Life Expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
written informed consent
Beschreibung

Informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy or nursing
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
documented history of congestive heart failure (chf), serious arrhythmia, or myocardial infarction (within 6 months)
Beschreibung

Congestive heart failure | Cardiac Arrhythmia Serious | Myocardial Infarction

Datentyp

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2,1]
C0003811
UMLS CUI [2,2]
C0205404
UMLS CUI [3]
C0027051
other invasive malignancy except nonmelanoma skin cancer or acute infection.
Beschreibung

invasive cancer | Skin carcinoma | Acute infection

Datentyp

boolean

Alias
UMLS CUI [1]
C0677898
UMLS CUI [2]
C0699893
UMLS CUI [3]
C0275518
radiation of measurable disease (except brain metastases)
Beschreibung

Radiation Measurable Disease | Metastatic malignant neoplasm to brain

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0851346
UMLS CUI [1,2]
C1513041
UMLS CUI [2]
C0220650
progressive brain metastases according to clinical or radiological criteria.
Beschreibung

Metastatic malignant neoplasm to brain Progressive

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0205329
brain metastases without prior radiation therapy
Beschreibung

Metastatic malignant neoplasm to brain Without prior radiation therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0332288
UMLS CUI [1,3]
C0279134
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Breast Cancer NCT00431795

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age 18-75 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Bone Marrow function | Absolute neutrophil count | Platelet Count measurement | Hemoglobin
Item
adequate bone marrow function (absolute neutrophil count >1000/mm^3, platelet count>100000/mm^3, hemoglobin>9gr/mm^3)
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0019046 (UMLS CUI [4])
Breast adenocarcinoma
Item
histologically- or cytologically- confirmed breast adenocarcinoma
boolean
C0858252 (UMLS CUI [1])
Anthracycline Antibiotics | Therapeutic procedure Advanced breast cancer
Item
no prior anthracycline-based chemotherapy as treatment of advanced breast cancer
boolean
C0003234 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C3495917 (UMLS CUI [2,2])
Prior Chemotherapy | Doxorubicin Adjuvant | Epirubicin Adjuvant
Item
no prior chemotherapy with ≥ 300mg/m2 doxorubicin or ≥ 540mg/m2 epirubicin as adjuvant setting
boolean
C1514457 (UMLS CUI [1])
C0013089 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
C0014582 (UMLS CUI [3,1])
C1522673 (UMLS CUI [3,2])
Interval Minimum Since cancer treatment
Item
at least 4 weeks interval since prior anticancer treatment
boolean
C1272706 (UMLS CUI [1,1])
C1524031 (UMLS CUI [1,2])
C1711239 (UMLS CUI [1,3])
C0920425 (UMLS CUI [1,4])
Measurable lesion Quantity | Secondary malignant neoplasm of bone | Ascites | Pleural effusion
Item
measurable disease as defined by the presence of at least one measurable lesion(except bone metastases, ascites or pleural effusions)
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0153690 (UMLS CUI [2])
C0003962 (UMLS CUI [3])
C0032227 (UMLS CUI [4])
Life Expectancy
Item
life expectancy > 3 months
boolean
C0023671 (UMLS CUI [1])
Informed consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnancy or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Congestive heart failure | Cardiac Arrhythmia Serious | Myocardial Infarction
Item
documented history of congestive heart failure (chf), serious arrhythmia, or myocardial infarction (within 6 months)
boolean
C0018802 (UMLS CUI [1])
C0003811 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
invasive cancer | Skin carcinoma | Acute infection
Item
other invasive malignancy except nonmelanoma skin cancer or acute infection.
boolean
C0677898 (UMLS CUI [1])
C0699893 (UMLS CUI [2])
C0275518 (UMLS CUI [3])
Radiation Measurable Disease | Metastatic malignant neoplasm to brain
Item
radiation of measurable disease (except brain metastases)
boolean
C0851346 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2])
Metastatic malignant neoplasm to brain Progressive
Item
progressive brain metastases according to clinical or radiological criteria.
boolean
C0220650 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
Metastatic malignant neoplasm to brain Without prior radiation therapy
Item
brain metastases without prior radiation therapy
boolean
C0220650 (UMLS CUI [1,1])
C0332288 (UMLS CUI [1,2])
C0279134 (UMLS CUI [1,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video